BioNexus Gene Lab Corp Quarterly Cost of Revenue in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
BioNexus Gene Lab Corp quarterly/annual Cost of Revenue history and growth rate from Q1 2018 to Q3 2024.
  • BioNexus Gene Lab Corp Cost of Revenue for the quarter ending September 30, 2024 was $2.3M, a 4.75% increase year-over-year.
  • BioNexus Gene Lab Corp Cost of Revenue for the twelve months ending September 30, 2024 was $8.01M, a 10.3% decline year-over-year.
  • BioNexus Gene Lab Corp annual Cost of Revenue for 2023 was $8.44M, a 12.7% decline from 2022.
  • BioNexus Gene Lab Corp annual Cost of Revenue for 2022 was $9.67M, a 12.9% decline from 2021.
  • BioNexus Gene Lab Corp annual Cost of Revenue for 2021 was $11.1M, a 14.7% increase from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $8.01M $2.3M +$104K +4.75% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-15
Q2 2024 $7.91M $1.69M -$541K -24.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $8.45M $2.02M +$8.51K +0.42% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $8.44M $2.01M -$494K -19.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-16
Q3 2023 $8.94M $2.2M -$76.2K -3.35% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-15
Q2 2023 $9.01M $2.23M +$6K +0.27% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $9.01M $2.01M -$664K -24.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $9.67M $2.5M -$237K -8.67% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-16
Q3 2022 $9.91M $2.28M -$591K -20.6% Jul 1, 2022 Sep 30, 2022 10-Q/A 2024-03-26
Q2 2022 $10.5M $2.22M -$403K -15.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-16
Q1 2022 $10.9M $2.67M -$194K -6.77% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $11.1M $2.74M -$1.01M -26.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $12.1M $2.87M +$298K +11.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $11.8M $2.62M +$1.68M +178% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $10.1M $2.87M +$452K +18.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $9.67M $3.74M +$3.69M +6540% Oct 1, 2020 Dec 31, 2020 10-K 2022-04-06
Q3 2020 $5.98M $2.57M +$2.55M +15469% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $3.43M $944K +$927K +5448% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $2.5M $2.41M +$2.43M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-18
Q4 2019 $71.1K $56.4K +$244K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-30
Q3 2019 -$173K $16.5K +$85.8K Jul 1, 2019 Sep 30, 2019 10-Q/A 2020-11-09
Q2 2019 -$258K $17K -$68.6K -80.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 -$190K -$18.8K -$6.29K -50.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 -$184K -$187K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-31
Q3 2018 -$69.3K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $85.6K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$12.5K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.